Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients (EVOLVE)
A Clinical Study Of Enadenotucirev Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer
Sponsor: Akamis Bio
A PHASE1/PHASE2 clinical study on Metastatic Bladder Cancer and Metastatic Colorectal Cancer, this trial is completed. The trial is conducted by Akamis Bio and has accumulated 9 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Feb 2023 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Apr 2020 [monthly]
Completed PHASE1_PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Akamis Bio
For direct contact, visit the study record on ClinicalTrials.gov .